 GENEVA, Jan. 11, 2023 PRNewswire SELUTION SLRTM, MedAlliances novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption IDE approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment of... The post MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB... 